Asahi Kasei announced that it will launch two new specialty grades in its Sonanos? portfolio.Paid samples are already available, and products manufactured in compliance with Good Manufacturing Practice (GMP) are scheduled for sale in 2027. Sonanos?
is a next-generation excipient designed to improve the formulation of injectable drugs. This aligns with the company?s long-term growth strategy to enhance its presence in the fast-growing pharmaceutical materials market. Global demand for biologics, peptides, and oncology therapies is increasing rapidly, creating pressure on pharmaceutical companies to solve formulation, drug persistence, and delivery challenges.
Sonanos? addresses these needs by enabling sustained release and enhanced solubility?key capabilities that can achieve long-acting injectables, formulate poorly water-soluble compounds, and expand therapeutic possibilities through overcoming formulation challenges. With samples of both grades with guaranteed analytical values now available for nonclinical development, Asahi Kasei is laying the foundation for broader adoption.
The company plans to supply products manufactured in compliance with GMP in 2027, meeting international guidelines for pharmaceutical excipients and impurities, which is necessary for clinical development. Sonanos? is also advancing through Asahi Kasei?s spin-out venture, DiveRadGel Inc., which applies the technology to cancer vaccine development.
The vaccine-grade Sonanos? DV has already entered GMP production to support early-stage clinical trials?demonstrating the platform?s commercial and therapeutic relevance.
